Mixed trend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Oct 23 · above the Ichimoku cloud · RSI 46 · MACD below its signal
| 0.1240 | 52-week high | +55.00% |
| 0.1100 | Previous week high | +37.50% |
| 0.1000 | Previous month high | +25.00% |
| 0.0853 | R3 (classic) | +6.67% |
| 0.0827 | R2 (classic) | +3.33% |
| 0.0813 | R1 (classic) | +1.67% |
| 0.0800 | Price now | |
| 0.0800 | Previous day high | −0.00% |
| 0.0787 | Pivot | −1.67% |
| 0.0773 | S1 (classic) | −3.33% |
| 0.0760 | Previous day low | −5.00% |
| 0.0747 | S2 (classic) | −6.67% |
| 0.0733 | S3 (classic) | −8.33% |
| 0.0590 | Previous week low | −26.25% |
| 0.0590 | Previous month low | −26.25% |
| 0.0400 | 52-week low | −50.00% |
None of the 29 investors followed here reported a position in INTI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a INTI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for INTI.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 73.3 | 2.6 | 36.2 | -17.4 | -5.6 | -5.9 | 0.0 | 11.3 | 12.4 | -20.0 | +77.8% | ||
| 2025 | -3.3 | 13.8 | -24.2 | 24.0 | -32.3 | 0.0 | 31.0 | -20.0 | 13.6 | 0.0 | 0.0 | -10.0 | −25.0% |
| 2024 | 8.7 | -20.0 | -12.5 | 22.9 | 2.3 | -10.2 | -17.7 | 13.8 | 14.9 | 0.0 | -9.4 | -22.1 | −34.8% |
| 2023 | -38.4 | 1.6 | -9.7 | -37.5 | -8.6 | 15.6 | -24.3 | 57.1 | 22.7 | -3.7 | 75.0 | 1.1 | −7.1% |
| 2022 | -12.7 | 20.6 | -17.1 | 9.9 | -36.1 | 8.7 | -38.0 | 43.5 | -41.6 | -5.8 | 36.7 | 47.8 | −34.0% |
| 2021 | 54.3 | 113.0 | -33.9 | -14.5 | 21.5 | 205.1 | -0.4 | -44.6 | 12.8 | 13.3 | -20.6 | 11.1 | +328.6% |
| 2020 | 16.1 | 15.4 | -10.7 | -23.9 | -9.8 | 106.5 | -41.1 | -10.7 | 0.0 | -14.0 | 4.7 | -22.2 | −37.5% |
| 2019 | 5.0 | 17.5 | 18.9 | -43.2 | 46.0 | 9.6 | -18.8 | 32.3 | -30.2 | 1.7 | -21.3 | 16.7 | −6.7% |
| 2018 | -4.4 | 20.8 | -9.7 | 3.1 | 25.9 | -5.9 | -12.5 | -2.5 | 17.2 | -12.5 | -42.9 | -62.5 | −76.1% |
| 2017 | -5.1 | -16.2 | -17.7 | 37.3 | 0.0 | -14.3 | 41.0 | -10.2 | 10.5 | -14.3 | -27.8 | -3.5 | −35.6% |
| 2016 | -23.1 | 0.0 | 50.0 | -24.7 | 54.9 | 30.3 | 18.4 | 44.4 | 2.6 | 8.0 | -13.7 | 4.6 | +200.0% |
| 2015 | 28.0 | -21.9 | 84.0 | -13.0 | -30.0 | -21.4 | -36.4 | 85.7 | 46.2 | -34.2 | 0.0 | 4.0 | +4.0% |
| 2014 | 265.9 | -40.0 | 11.1 | 16.0 | -35.3 | -32.0 | 65.7 | -17.2 | -14.3 | -16.7 | 20.0 | 4.2 | +52.4% |
| 2013 | -23.7 | 44.4 | -36.9 | −30.5% |
TimeframesUp on the monthly, down on the daily, mixed on the weekly.
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
No analyst coverage for this instrument.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.